08:49:36 Europe / Stockholm
Svenska | English

Newbury Pharmaceuticals

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-01-15 Kvartalsrapport 2025-Q1
2025-01-15 Årsstämma 2025
2024-10-09 Bokslutskommuniké 2024
2024-07-10 Kvartalsrapport 2024-Q3
2024-04-10 Kvartalsrapport 2024-Q2
2024-01-11 Ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10 Årsstämma 2024
2024-01-10 Kvartalsrapport 2024-Q1
2023-10-11 Bokslutskommuniké 2023
2023-07-14 Kvartalsrapport 2023-Q3
2023-04-12 Kvartalsrapport 2023-Q2
2023-01-12 Ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11 Kvartalsrapport 2023-Q1
2023-01-11 Årsstämma 2023
2022-10-13 Bokslutskommuniké 2022
2022-07-06 Kvartalsrapport 2022-Q3
2022-04-13 Kvartalsrapport 2022-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.
Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14
2023-06-13 17:40:00

Newbury Pharmaceuticals has previously announced that the interim report for the period September 2022 – May 2023 will be published on July 7. The board has now decided to advance the report date to June 14.

The reason for this decision is that work on the report has gone faster than expected and is available for publication.

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden